To address this scenario, guidelines have recommended combination therapy involving a xanthine oxidase inhibitor (XOI) alongside a uricosuric agent for patients with acute gout who cannot achieve management and treatment targets through XOI monotherapy alone. Here, XDH is linked to gout.